Market research
4512.TSE Wakamoto Pharmaceutical Co.,Ltd
TSE JPY Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10B
- P/E ratio
- 30.25
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.45
Profile
Instrument facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- JP3991200001
- Market cap
- 10B
- P/E ratio
- 30.25
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.45
About
About Wakamoto Pharmaceutical Co.,Ltd
Wakamoto Pharmaceutical Co.,Ltd. is engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. It operates through four segments: Pharmaceutical Business, Healthcare Business, Global Business, and Real Estate Leasing Business. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste. The company was formerly known as Society for Nutrition and Raising Children Co., Ltd. and changed its name to Wakamoto Pharmaceutical Co.,Ltd. in July 1943. Wakamoto Pharmaceutical Co.,Ltd. was founded in 1929 and is headquartered in Tokyo, Japan.
Research context
Wakamoto Pharmaceutical Co.,Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4512.TSE discussion.
5 years, 7 months ago
Wakamoto Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 6.1% above its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
Wakamoto Pharmaceutical Co.,Ltd's total revenue sank by 22.9% to $2B since the same quarter in the previous year.
Its net income has increased by 19.7% to $76M since the same quarter in the previous year.
Based on the above factors, Wakamoto Pharmaceutical Co.,Ltd gets an overall score of 3/5.